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Purpose: Transrectal ultrasound (TRUS)-guided biopsy is the standard procedure for evaluating the
presence and aggressiveness of prostate cancer. TRUS biopsy involves tissue removal, and suffers
from low core yield as well as high false negative rate. A less invasive and more accurate diagnostic
procedure for prostate cancer is therefore highly desired. Combining the optical sensitivity and ultra-
sonic resolution to resolve the spatial distribution of the major molecular components in tissue, pho-
toacoustic (PA) technology could be an alternative approach for the diagnosis of prostate cancer. The
purpose of this study was to examine the feasibility of identifying aggressive prostate cancer using
interstitial PA measurements.
Methods: Seventeen patients with prebiopsy magnetic resonance imaging (MRI), TRUS biopsies,
and planned prostatectomies were enrolled in this study. The interstitial PA measurements were
achieved using our recently developed needle PA probe, which was inserted into the ex vivo prostates
in the fashion of a biopsy needle. A total of 70 interstitial PA measurements were acquired. The PA
measurements were quantified by a previously established PA physio-chemical analysis (PAPCA)
method. The histology has confirmed the nonaggressive and aggressive cancerous conditions at the
insertion locations. The diagnostic accuracy was also compared to that provided by the prebiopsy
MRI.
Results: The quantitative study shows significant differences between the individual parameters of
the nonaggressive and the aggressive cancerous regions (P < 0.005). Multivariate analysis of the
quantitative features achieved a diagnostic accuracy of 78.6% for differentiating nonaggressive and
aggressive prostate cancer tissues.
Conclusions: The proposed procedure has shown promises in the diagnosis of aggressive prostate
cancer. © 2018 American Association of Physicists in Medicine [https://doi.org/10.1002/mp.13061]
Key words: medical imaging, optoacoustics, photoacoustic physio-chemical analysis, photoacoustic
spectral analysis, prostate cancer
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1. INTRODUCTION
During the past two decades, prostate cancer has become the
most commonly diagnosed cancer in American men, with an
annual incidence rate much higher than that of any other
cancer.1 Currently, a major challenge to the diagnosis of pros-
tate cancer is to identify aggressive cases in avoidance of
metastasis.2 Transrectal ultrasound (TRUS) guided biopsy is
the standard procedure for evaluating the presence and
aggressiveness of prostate cancer. During the procedure, 16
or 18 gauge biopsy needles (with diameters of 1.29 and
1.02 mm, respectively) extracts 15 mm biopsy cores from the
prostate.3 Each biopsied tissue is examined by a pathologist
and assigned a Gleason score,4 a highly prognostic architec-
ture-based grading system for prostate cancer. Tissues with
Gleason scores equal or larger than 7 (3 + 4) are considered
aggressive cancer.4 Biopsy procedures identifying any
aggressive tissues will trigger the therapeutic procedures.2
Since TRUS imaging can only define the contour of the pros-
tate and the biopsies are typically performed following a pre-
determined pattern overlaid onto the prostate contour, 20–
30% of biopsy procedures were found false negative.3,5,6 By
sampling more than 50 sites, transperineal saturated biopsies
have achieved better sensitivity to aggressive prostate cancer.7
Only 10% of the sample cores are clinically significant,
whereas the initial biopsy can still produce 20% false nega-
tive diagnoses.6 Magnetic resonance imaging (MRI) has been
introduced to improve the identification of clinically signifi-
cant prostate cancer in men with initial negative biopsies.8–10
However, the evaluation of MRI images requires experienced
radiologists, and even experienced radiologists have only
moderate inter-rater repeatability.11 The suspicious aggressive
cancer regions in MRI still require biopsy core extractions for
confirming the disease conditions in the prostates.12 A diag-
nostic modality that can assess the aggressiveness of prostate
cancer in vivo without core extractions could significantly
reduce patient anxiety, pain and postprocedure complica-
tions.13
Photoacoustics (PA) is a technology combining the sensi-
tivity of optical spectroscopy and the resolution of ultrasound
imaging. Our recently developed PA spectral analysis (PASA)
method14–17 has demonstrated the capability of determining
intraocular tumor types18 and identifying aggressive prostate
cancer.19 PASA at multiple wavelengths, namely PA physio-
chemical analysis (PAPCA), has shown the capability of
comprehensively analyzing the microarchitectures associated
with the major molecular components within the assessed tis-
sue volume. PAPCA has been validated in identifying the dis-
eased conditions during the progression of nonalcoholic fatty
liver diseases.14,15 PASA and PAPCA are potential tools for
prostate cancer diagnosis, as the incidence of prostate cancer
is associated with both molecular and architectural changes.
In our previous study, the PA spectral parameters showed
strong correlation with the Gleason scores in human prostate
cancer tissues19 and the vasculature densities in xenograft
prostate cancer tumors in mice.20 Other studies implementing
optical modalities including PA imaging have also
demonstrated the changes of molecular components such as
lipid,21,22 collagen23–25 and hemoglobin21,22,26 in prostate
cancer tissue.
However, the strong diffusion of optical energy and attenu-
ation of high-frequency acoustic signals by biological tissue
undermined the capability of PA measurements in quantify-
ing the molecular components and microarchitectures in deep
prostate tissue. Therefore, the superficial illumination
approach used in our previous studies14,15 is not applicable in
the in vivo prostate imaging scenario. Most of the previous
studies on the PA imaging of prostate cancer were performed
with sliced prostate tissues ex vivo.19,21,22 Our recently devel-
oped needle PA probe facilitates the delivery of relatively uni-
form illumination along a fiber optic diffuser, and the
reception of the high frequency PA signals with a needle
hydrophone from nearby tissues.27 Such configuration allows
the minimally invasive acquisition of PA signals with suffi-
cient temporal length and narrow dynamic range in deep tis-
sue for statistically based PASA.
In this study, for the first time, we have examined the
feasibility of interstitial assessment of prostate cancer using
the needle PA probe in intact human prostates ex vivo. The
quantitative analysis methods established in our previous
studies14,15 (i.e., PAPCA) were implemented to the measure-
ments. The quantified diagnostic factors were compared to
the pathology results as well as the prebiopsy MRI diagnoses.
2. MATERIALS AND METHODS
2.A. Prebiopsy MRI diagnosis and sample
collection
In this study, 17 intact prostate samples were procured in
Tongji Hospital in Shanghai, China. All procedures in this
study were approved by the Institutional Review Board of
the Tongji Hospital. The subjects were provided with written
consent. The patients have been examined by multiparamet-
ric MRI (Verio 3.0 T, Siemens, Munich, Germany) and
TRUS biopsy before the prostatectomy procedures. The con-
figuration of the MRI scanning follows the standards in
prostate imaging — reporting and data system.28 The crite-
ria of the aggressive cancer MRI diagnostic parameters
include,28 (a) the disease anatomies and the enlarged vol-
umes of the prostates revealed by T2-weighted imaging, (b)
the presence of hyperintense b-value and hypointense appar-
ent diffusion coefficient in diffusion weighted imaging, and
(c) diffusion enhancement in dynamic contrast enhanced
imaging. The regions with less yet observable aggressive
cancer characteristics were categorized as “suspicious
cancerous” regions and also delineated for guiding the
biopsy procedures.
The interstitial measurements by needle PA probes were
acquired at a total of 70 locations. The measurement loca-
tions were marked by a syringe needle after the measure-
ments. The prostates were subsequently diced without
interfering with the needles and sliced for histology. The
pathology has confirmed that 44 nonaggressive (i.e.,
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Gleason < 3 + 4) and 26 aggressive cancerous regions
(Gleason score ≥ 3 + 4) were sampled.
2.B. Experiment setup
Figure 1(a) illustrates the experiment setup. In brief, the
measurements were acquired by our previously developed nee-
dle PA probe27 consisting of a fiber optic diffuser and a needle
hydrophone. The fiber optic diffuser was made from a single
optical fiber with a 600 lm core diameter, a 0.39 numerical
aperture, and a 2 cm emission end. The needle hydrophone
(HNC1500, ONDA Corp., Sunnyvale, CA) has a diameter of
1 mm, and a bandwidth of 1–10 MHz and preamplification of
40 dB. The needle PA probe was inserted into the ex vivo
prostates at the suspicious nonaggressive and aggressive can-
cer locations. A tunable optical parametric oscillator (OPO)
laser (Phocus Mobile, OPOTEK, Carlsbad, CA) was used to
generate illumination in the range of 690–950 and 1200–
1700 nm at the intervals of 10 nm. The laser beam with
18 mJ per pulse energy was collimated to approximately
1 mm in diameter and coupled into the fiber optic diffuser.
Considering the approximately 30% coupling efficiency,
optical energy density of approximately 14 mJ/cm2 per pulse
was delivered to the illumination surface of the needle PA
probe surface with an area of approximately 0.377 cm2
(=p 9 600 lm 9 2 cm). The signal received by the needle
hydrophone was amplified by 40 dB (5072PR, Olympus
NDT, Waltham, MA) and averaged 10 times before being
recorded by an oscilloscope (TDS 540, Tektronix, Beaverton,
OR). With the laser repetition rate of 10 Hz, measurements at
each sampling location, including the data transfer between
devices took approximately 2 min. A representative signal
acquired by the experiment is shown in Fig. 1(b). Similar to
the observation in our previous study, the signal possesses nar-
row dynamic range along the temporal extension correspond-
ing to the length of the fiber optic diffuser.
2.C. Physio-chemical spectra (PCSs) of the
nonaggressive and aggressive cancerous locations
in the prostate
Our previously developed data processing methods15 were
implemented in this study. The power spectra of the PA sig-
nals were calculated using the Welch’s approach29 within the
frequency range of 0–8.5 MHz with a step size of 0.1 MHz.
The power spectra were arranged in the order of the illumina-
tion wavelengths. A 2-dimensional (2D) spectrogram, namely
a PCS,15 was formed for each measurement location. Follow-
ing the methods in Ref. [15], by comparing to the optical
absorption profiles in Fig. 2(c), one can explicitly correlate
the stripe patterns in the PCS [marked by the color contours
in Figs. 2(a) and 2(b)] with the major molecular components
within the assessed tissue volume. The intensities of the
stripe patterns, namely PCS fingerprints, presented in
pseudo-color, render the relative contents of the components,
while the extensions of the fingerprints along the y-axis are
relevant to the dimensions of the microarchitecture associated
with each component.
2.D. Quantification of the diagnostic information in
the PCS using PASA
We have successfully quantified the intensities and the
extensions of the fingerprints in the PCSs using PASA in our
previous study.15 Figure 3 illustrates the PASA method using
the PA signal power spectra at 700 nm. The power spectra
were first fit to a linear model. A simple linear model was
used as we are only interested in the ratio between the relative
high- and low-frequency components. The slope, midband-fit
and intercept of the linear models were quantified. The slope
represents the heterogeneity formed by the molecular compo-
nent targeted by the specific wavelength, whereas the inter-
cept and midband-fit represent the relative content of the
molecular component. Since two of the three PASA parame-
ters can derive the third, this study only discusses slope and
midband-fit. The power spectra in Fig. 3 tend to be over-
whelmed by noise above 8.5 MHz and a high pass filter was
used to remove the low frequency components generated due
to the illumination of the needle hydrophone. The PA fre-
quency range of [0.5, 8.5] MHz was observed.
The PASA slopes and midband-fits were quantified at the
center of the PCS fingerprint correlated with each of the
major molecular components in the prostates, including
hemoglobin (700 nm), lipid (1220 nm), and collagen
(1370 nm). The differences between the quantitative features
derived from nonaggressive and aggressive cancerous regions
were quantified using the one-tailed t-tests in MATLAB
(Mathworks, Natick, MA). The receiver operating character-
istic (ROC) analysis was also performed with the slope
values.
FIG. 1. Experiment system. (a) The laser and the oscilloscope were synchronized. A personal computer was used to store the PA signals. The central bottom
insertion shows the illumination by the fiber optic diffuser. (b) Representative signals acquired. [Color figure can be viewed at wileyonlinelibrary.com]
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2.E. Support vector machine (SVM) analysis of the
quantitative features
The PASA parameters showing significant difference
between the nonaggressive and aggressive prostate tissues
were also analyzed in combination using a multivariate analy-
sis method, namely SVM.31 A MATLAB toolbox, LIB-
SVM,32 was implemented to the PASA parameters. This
study selected the C-type SVM model. The optimal parame-
ter of the selected SVM, i.e., the regularization parameter C
was iteratively searched in the range of 0.1 to 100. Similar to
our previous study, the dataset was divided into four groups
by the prostate samples (prostates number 1–4, 5–8, 9–12,
and 13–17) for blindly testing the proposed categorization
based on SVM. The scheme uses three of the four data
groups the SVM in turns and the rest one for testing the
trained SVM. The accuracy, the sensitivity, and the speci-
ficity of the SVM was quantified.
3. RESULTS
3.A. Preliminary diagnosis by MRI and histology
results
Figure 4 shows the representative nonaggressive regions,
suspicious aggressive cancerous and aggressive cancerous
MRI images with the suspicious and aggressive cancerous
regions delineated. The MRI diagnosis are listed later in the
Table I and compared to the PA diagnosis.
The histology in Fig. 5 shows the decrease of the connec-
tive tissues which consist of lipid and collagen [red-pink
regions]. The resolvable microscopic features (>150 lm,
generating signals within the range of 0–10 MHz) formed by
the connective tissues have decreased correspondingly.
3.B. PCSs of nonaggressive and aggressive
cancerous prostate tissues
By comparing the PCS fingerprints in Figs. 2(a) and 2(b)
to the optical absorption spectra in Fig. 2(c), one is able to cor-
relate hemoglobin, lipid, collagen components with the finger-
prints centered at around 700, 1220, and 1370 nm. The
fingerprint in the 1400–1500 nm range delineated by the black
contours correlated with the overlapping absorption profiles of
water and lipid. Since the decoupling of the contribution of the
two molecular components in such 2D spectrogram is difficult,
the fingerprint at this wavelength range was not quantified.
As shown in Figs. 2(a) and 2(b), the fingerprints in
aggressive cancerous PCS, compared to the nonaggressive
one, demonstrates lighter color. Such observation indicates
that the content of the corresponding molecular components
are lower in the aggressive regions. The fingerprints of
aggressive cancer tissue also show less extended and the
heterogeneous architectures formed by these molecular com-
ponents have decreased. These observations agree with the
histology in Fig. 5.
3.C. Statistics of the quantitative features in PCS
The PASA slopes and midband-fits were quantified from
the PCS fingerprints acquired at all the sampled tissue
locations. The midband-fits derived at the lipid (1220 nm)
and collagen (1370 nm) wavelengths demonstrated slight
decrease in aggressive cancerous regions, which agrees with
the histology in Fig. 5 and previous studies.21,23–25 The mid-
band-fits, i.e., the PA signal magnitudes, at 700 nm of the
aggressive cancerous tissues demonstrate no significant dif-
ference. Such observation agrees with a previous study.26 The
slopes at all the three wavelengths decreased in aggressive




FIG. 2. PCSs acquired by needle PA probes in (a) nonaggressive and (b)
aggressive cancerous prostate tissues. (c) The relative optical absorption
spectra of the major molecular components in biological tissue.30 [Color fig-
ure can be viewed at wileyonlinelibrary.com]
FIG. 3. Illustration of PASA. The PA signals were acquired at 1220 nm.
[Color figure can be viewed at wileyonlinelibrary.com]
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As mentioned in the method section, the differences
between the PASA parameters of nonaggressive regions and
aggressive cancerous regions were quantified by one-tailed
t-tests. Only the slopes at 1220 nm and 1370 nm showed
significance. The P-values were shown in Figs. 6(e) and 6(f).
Such results agree with our previous conclusion14,15 that
PASA slope is a parameter less subject to the uncertain fac-
tors such as illumination energy fluctuations.
Figures 7(a), 7(b), 7(c) show The ROC analyses of the
slope values derived at each individual wavelengths, respec-
tively. The optimal diagnostic performance is at the point
where the ROC curve is farthest from the diagonal line in
Fig. 7. Therefore, identifying the aggressive cancerous
regions by slopes less or equal than 1.20 at 1220 nm lead
to a diagnostic accuracy of 70.0% (49/70) with sensitivity of
88.5% and specificity of 59.1%, respectively. Similarly, iden-
tifying the aggressive cancerous regions by slopes at
1370 nm less or equal than 0.952 lead to a diagnostic accu-
racy of 70.0% (49/70) with sensitivity of 84.6% and speci-
ficity of 61.4%, respectively.
3.D. SVM categorization
The regularization parameter in the SVM32 was deter-
mined as 25 by iterative attempts using the fourfold valida-
tion scheme. Figure 7(d) shows ROC analysis of the decision
values generated by the SVM models. An AUC of 0.811 has
been achieved by combining the slopes at all the three wave-
lengths.
(a) (b) (c)
FIG. 4. Representative MRI images with (a) nonaggressive, (b) suspicious aggressive cancerous, and (c) aggressive cancerous regions in prostates. The grayscale
is in arbitrary unit. [Color figure can be viewed at wileyonlinelibrary.com]
TABLE I. Comparison between SVM categorization results and the standard pathologic diagnosis. NA: nonaggressive; A: aggressive.
Group # Prostate # PA-Meas. # PA-TP PA-TN PA-FP PA-FN PA diagnosis MR diagnosis Whole prostate pathology
1 1 5 2 2 0 1 A A A
2 5 1 2 1 1 A A A
3 5 1 1 0 3 A A A
4 6 0 6 0 0 NA A NA
2 5 4 1 1 1 1 A A A
6 4 0 4 0 0 NA Suspicious NA
7 2 1 1 0 0 A Suspicious A
8 5 0 5 0 0 NA Suspicious NA
3 9 3 1 1 0 1 A Suspicious A
10 5 2 1 1 1 A Suspicious A
11 5 1 2 2 0 A Suspicious A
12 4 0 2 2 0 NA NA NA
4 13 5 3 2 0 0 A A A
14 3 3 0 0 0 A A A
15 3 0 3 0 0 NA NA NA
16 3 0 3 0 0 NA Suspicious NA
17 3 2 1 0 0 A Suspicious A
Total 70 18 37 7 8
(a) (b)
FIG. 5. Representative histology of (a) nonaggressive and (b) aggressive
cancerous prostate tissues. The pink regions marked by the black contours
were the connective tissues formed by lipid and collagen components. [Color
figure can be viewed at wileyonlinelibrary.com]
Medical Physics, 45 (9), September 2018
4129 Huang et al.: Interstitial prostate cancer diagnosis 4129
Table I shows the comparison between the pathologic diag-
nosis, the in vivo MRI diagnosis and the ex vivo PA diagnosis.
The first row shows the grouping of the prostate specimens in
the fourfold training-testing cycles. The second and third row
shows the serial numbers of the prostate specimens and the
number of interstitial PA measurements in each prostate. As
shown in Fig. 7(d), using the criteria that the SVM decision
values less or equal than 0.0458 indicate aggressive cancers,
the diagnostic accuracy for individual interstitial measurements
is 78.6% (54/70), with the sensitivity and specificity of 65.4%
and 84.1%, respectively. In addition, at least one aggressive
cancerous region was correctly identified in the prostates with
aggressive cancers. Considering identifying the suspicious
regions can effectively guide the TRUS biopsies, MRI has also
assisted in identifying most of the aggressive cancer cases,
except a false-positive case was found.
4. DISCUSSION
Taking advantage of the optical energy propagation, the
interstitial measurements, without tissue removal, could
assess tissue volume much larger than that of a biopsy
core. The comprehensive assessment of the entire prostate
volume thereby becomes possible. One major issue with
the interstitial measurement approach is that the needle PA
probe has varied penetration at the different wavelengths.
And the one dimensional measurement cannot provide suf-
ficient spatial resolution to resolve the assessed volume.
However, by assuming that prostate tissue possesses simi-
lar optical properties and the cancerous regions are small
perturbations to the light propagation, the penetration of a
specific wavelength at individual prostates is approxi-
mately the same. The comparisons between the PCSs at
the same wavelengths are valid.
The prototype needle PA probe will be further miniatur-
ized into the geometry of a biopsy needle. The total detec-
tion length of the needle PA probe will be kept as 20 mm,
which matches the length of the functional tip of a biopsy
needle. Needle hydrophone and fiber optic diffuser with
smaller diameters will be integrated into a metal sheath
with a side window for light delivery and acoustic signal
reception. Such design will be fully compatible with the
TRUS guidance for the insertion of the needle PA probes.
A smaller detection surface of the hydrophone might
reduce the sensitivity of the probe, especially to the high-
frequency signal components. The use of thinner optical
fiber may also reduce the signal-to-noise ratio of the mea-
surements. Low-noise amplifier will have to be used to
ensure the acquisition of sufficient high-frequency signal
components encoding the tissue architectures. In addition,
we may have to lower the upper limit of the frequency
range to minimize the interference of noise floor.
The slopes of the nonaggressive and aggressive cancer-
ous tissues have shown statistically significant differences
at both 1220 and 1370 nm. This agrees with the fact that
the major change in the cancerous prostate tissues occur
FIG. 6. PASA parameters quantified from the PCSs. The nonaggressive and aggressive cancerous datasets include 44 and 26 samples, respectively.. (a–c) are the
boxplots of midband-fits derived from PASA at 700, 1220, and 1370 nm, respectively. (d–f) are the boxplots of slopes derived from PASA at 700, 1220, and 1370
nm, respectively. The red lines represent the medians of the datasets. The upper and lower edges of the boxes are the 25th and 75th percentiles, respectively. The
dashed lines extend to the most extreme data points and do not consider outliers. The outliers are plotted as “+”. [Color figure can be viewed at wileyonlinelibra
ry.com]
FIG. 7. ROC analysis of the PASA slopes at 1220 nm (a) and 1370 nm (b). [Color figure can be viewed at wileyonlinelibrary.com]
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in the tissue microscopic architecture.4 However, the con-
nective tissues observed in this study are indirect represen-
tation the gland architectures, i.e., Gleason grading, which
is the standard pathological diagnosis of prostate cancer.
Our previous study on PA imaging of prostate cancer tissues
with H&E staining of the cellular structures has shown the
capability of quantifying the Gleason scores.33 A previous
study34 has demonstrated that PA imaging can produce images
comparable to H&E stained histology by using ultraviolet
(UV) wavelengths in vivo. UV illumination therefore will allow
the direct observation and quantification of the Gleason pat-
terns. The future work of this study is therefore to include PA
measurements at UV wavelength for more comprehensive
diagnostic information.
The SVM approach combining quantitative parameters at
multiple wavelengths has demonstrated better diagnostic per-
formance than differentiating the nonaggressive and aggres-
sive samples using individual wavelengths. This is because
the use of multiple parameters improves the separation of the
datasets in higher dimension. Therefore, including the mea-
surements at UV wavelength are expected to further improve
the accuracy of the proposed diagnostic approach.
5. CONCLUSION AND FUTURE WORKS
This study investigates a minimally invasive and intersti-
tial diagnostic procedure based on a needle PA probe for the
identification of aggressive prostate cancer. Experiment
results with intact ex vivo human prostates have demonstrated
the feasibility and decent accuracy of the proposed
approaches. Future works will be targeted at miniaturizing
the needle PA probe for clinical translation and enriching the
diagnostic information by covering more molecular compo-
nents. The miniaturized needle PA probe will fit perfectly
into the established TRUS biopsy procedure and minimize
the necessity of tissue core extraction. The proposed intersti-
tial PA measurements approach will reduce the complication
of the biopsies, provide reliable diagnosis, and improve the
outcomes as well as the quality of life for the patients.
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